HPR31 Is the UK’S Ilap Process Delivering Its Intended Benefits? a Review of Access to Orbis Designated Oncology Products within the UK
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1349
https://www.valueinhealthjournal.com/article/S1098-3015(23)04479-0/fulltext
Title :
HPR31 Is the UK’S Ilap Process Delivering Its Intended Benefits? a Review of Access to Orbis Designated Oncology Products within the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04479-0&doi=10.1016/j.jval.2023.09.1349
First page :
Section Title :
Open access? :
No
Section Order :
10811